Related Experiment Video

Updated: Nov 29, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

673

Obesity and GLP-1

Alejandra Perez-Montes DE Oca1, Silvia Pellitero2, Manel Puig-Domingo1

  • 1Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital and Research Institute, Autonomous University of Barcelona, Badalona, Spain.

Minerva Endocrinology
|November 20, 2020
PubMed

Insights

Glucagon-like-peptide-1 receptor agonists offer an effective, less invasive treatment for obesity. These incretin-based drugs promote weight loss by increasing satiety and slowing digestion.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Obesity is a growing global public health concern requiring effective interventions.
  • Bariatric surgery is effective for morbid obesity but is invasive.
  • Less aggressive treatment options for obesity are needed.

Purpose of the Study:

  • To review the efficacy of glucagon-like-peptide-1 (GLP-1) receptor agonists for obesity treatment.
  • To discuss GLP-1 use in patients with and without diabetes.
  • To include recent findings on oral semaglutide for obesity.

Main Methods:

  • Review of existing clinical data and studies on GLP-1 receptor agonists for weight management.
  • Analysis of pharmacological actions of GLP-1, including insulin secretion, satiety, and gastric emptying.
  • Inclusion of data from trials involving liraglutide and semaglutide.

Main Results:

  • GLP-1 receptor agonists demonstrate significant weight loss effects.
  • Liraglutide (3 mg) is FDA-approved for obesity treatment, yielding up to 8.5 kg weight loss.
  • GLP-1 agonists exert peripheral and central effects contributing to weight reduction.

Conclusions:

  • GLP-1 receptor agonists represent a promising therapeutic class for obesity management.
  • These agents offer a valuable alternative to more invasive treatments.
  • Ongoing research, including oral semaglutide, continues to expand treatment options for obesity.

More Related Videos

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.5K
A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.9K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
639
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
121
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
952
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
86
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
99
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
393